Murphy, Senate Democrats Press Pharmaceutical Companies For Evidence Of Cost Savings For Americans Following Secret Deals With Trump

WASHINGTON-U.S. Senator Chris Murphy (D-Conn.), a member of the U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee, joined six Senate Democrats in an effort to continue seeking details from major pharmaceutical companies about their so-called deals with the Trump administration, in particular, any evidence that these deals will benefit American patients or lower drug prices.

"We write today to seek more information from [company] about which drugs are subject to the Medicaid components of your agreement with the Trump administration and whether the prices you will make available on these drugs are actually lower than the net pricing states currently receive on the same products in Medicaid," the senators wrote. "It is difficult to discern what American patients and taxpayers stand to gain from your agreement with the Trump Administration."

The letters, sent to AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, and Sanofi, ask for specific pricing information on which drugs will be affected by the announcements, what the "most favored nation" price is for those drugs, and what state Medicaid programs will pay in the wake of these announcements.

The letter was co-signed by U.S. Senators Ron Wyden (D-Ore.), Jeff Merkley (D-Ore.), Dick Durbin (D-Ill.), John Hickenlooper (D-Colo.), Amy Klobuchar (D-Minn.) and Elizabeth Warren (D-Mass.).

The full text of the letter can be found here.